Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) will report third-quarter 2025 financial results on Wednesday, November 5, 2025 after market close.
The company said a senior management webcast will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. Investors can listen live or access the archived webcast at https://ir.revmed.com/events-and-presentations. A replay will be available on the company website for at least 14 days following the live event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RVMD gained 1.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When will Revolution Medicines (RVMD) report Q3 2025 financial results?
What time is the Revolution Medicines (RVMD) Q3 2025 webcast on November 5, 2025?
Where can I listen to the Revolution Medicines (RVMD) Q3 2025 earnings webcast?
How long will the Revolution Medicines (RVMD) Q3 2025 earnings replay be available?
Who will present on the Revolution Medicines (RVMD) Q3 2025 earnings call?
